【硅谷银行】医疗保健投资和退出-2025.1_6页_697kb

Summary of Healthcare Investments and Exits Annual Report 2024

Core Content

The Healthcare Investments and Exits Annual Report 2024 provides an overview of the current state and future outlook of the healthcare innovation ecosystem, focusing on Biopharma, Healthtech, Dx/Tools, and Device sectors. The report highlights the growing role of AI in biopharma, the market dynamics for exits, and the government's influence on healthcare innovation.

Main Points

AI in Biopharma

• Biopharma AI is the dominant trend of 2024, with $5.6B invested, a 3X YoY increase.
• AI is being used to design novel proteins, especially in antibody and DNA/RNA binding protein development.
• The first entirely AI-designed drugs are now in clinical trials, and 2025 is expected to be a "prove-it" year for AI drug discovery.
• Xaira, a two-year-old company, received a $1B Series A round, indicating strong investor confidence in AI-driven protein design.

Exit Market Trends

• Late-stage biotech companies are still waiting for a more favorable market environment.
• A few companies have filed for IPOs in 2025, and positive performance from 2024 IPOs could boost investor confidence.
• The M&A market remains uncertain, with buyers and investors waiting for more clarity.
• Down rounds are becoming more acceptable, allowing companies to continue development without fear of dilution.

Government Influence

• The federal government plays a crucial role in shaping the healthcare innovation landscape.
• Expedited FDA approvals could accelerate the introduction of new treatments.
• Changes in SaMD regulations may benefit clinical decision support and device markets.
• Maintaining the FDA's reputation as a gold standard for safety is essential for building trust in new technologies.

Key Sectors Overview

Biopharma

• Clinical assets and pharma partnerships remain strong for biopharma startups.
• AI continues to be a major driver of innovation and investment, with a focus on protein design and drug discovery.

Healthtech

• Healthtech has seen less volatility in funding rounds.
• Proven track records and strong histories are key for securing investment.
• Incumbents are still struggling with exits, with undisclosed M&A being more common than public transactions.

Dx/Tools

• The peak of devaluations and down rounds may have passed.
• Innovations in precision diagnostics and liquid biopsy are attracting investment.
• These companies are well-positioned to support AI initiatives by providing data.

Device

• Hospitals are emerging as a key market for device startups, especially in acute care.
• Imaging and monitoring technologies are restoring interest in the device sector.
• Early-stage investing accounts for nearly a quarter of all investment since 2023.

Investor Sentiment

• Total investment has decreased from recent peaks but outpaced 2021 in the number of deals.
• Investors are more willing to bet on companies with clinical products or a strong mix of technology and founders.
• VCs are resetting portfolios, focusing on quality and long-term potential.

Trending Areas

1. Biotech AI Solutions

   • $5.6B invested in 2024, a 3X YoY increase.
   • AI is revolutionizing drug discovery and protein design.

2. Planting Seeds

   • Seed rounds increased to 40% of all deals, showing increased confidence in early-stage ventures.

3. Down Rounds Are Okay

   • Companies are becoming more open to down rounds, enabling continued development and innovation.

Lead Authors

• Jackie Spencer (Head of Relationship Management for Life Science & Healthcare Banking)
• Raysa Bousleiman (Vice President, Healthcare Venture Capital Relationship Management)
• Tim Lew (Director of Business Development for Startup Banking-Life Science)

Acknowledgements and Contributors

• The report is supported by subject-matter experts from Civilization Ventures, Deerfield, Lightspeed, and the Institute for Protein Design.
• Tyler Dean (Vice President, Biotech, Tools, & Diagnostics Relationship Management) is a key contributor.

Disclaimers

• The views expressed are those of the authors and do not reflect SVB's stance.
• Investment products are not insured or guaranteed.
• Investors should seek professional advice before making any decisions.

This report underscores the transformative potential of AI in healthcare and the evolving dynamics of the investment and exit markets. As the industry moves toward long-term innovation and commercialization, the role of venture capital and government policy will be critical in shaping the future of the sector.